Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 860 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Elevation Oncology Inc | ELEV | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.01 | -0.25% | 4.04 | 08:11:11 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.05 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 6 | 860 | - | 0.363 - 5.89 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:19:06 | 50 | $ 4.14 | USD |
Elevation Oncology Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 197.04M | 48.65M | - | 0 | -45.7M | -0.94 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Elevation Oncology News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ELEV Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.48 | 4.525 | 3.70 | 4.07 | 615,514 | -0.44 | -9.82% |
| 1 Month | 4.59 | 5.8299 | 3.70 | 4.82 | 899,914 | -0.55 | -11.98% |
| 3 Months | 3.00 | 5.8299 | 2.50 | 3.94 | 1,185,473 | 1.04 | 34.67% |
| 6 Months | 0.66 | 5.8299 | 0.363 | 2.53 | 1,755,650 | 3.38 | 512.12% |
| 1 Year | 1.83 | 5.89 | 0.363 | 2.97 | 1,418,324 | 2.21 | 120.77% |
| 3 Years | 14.00 | 16.22 | 0.363 | 3.05 | 633,499 | -9.96 | -71.14% |
| 5 Years | 14.00 | 16.22 | 0.363 | 3.05 | 633,499 | -9.96 | -71.14% |
Elevation Oncology Description
| Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition. |
